Effect of high-dose steroid therapy on T-cell subpopulations. A longitudinal study in MS patients.
Lymphocyte subpopulations, T cell activation antigens, and serum levels of interleukin 2 (IL-2) and soluble IL-2 receptor (sIL2R), were studied in relapsing-remitting MS (RR-MS) patients before and after high-dose steroid therapy. Prior to therapy, a minority of patients showed increased HLA-DR antigen expression, and an increased number of CD16+ and CD19+ cells. Steroid treatment induced a significant increase in HLA-DR and CD19 expression, a significant reduction in CD16+, CD57+, and CD8+ CD57+ cells, and a slight, non-significant, decrease in IL-2 and sIL-2R levels and CD25 expression on CD4+ T lymphocytes.
Gallo
P
P
Institute of Neurology, Second Neurologic Clinic, University of Padua, School of Medicine, Italy.
Chiusole
M
M
Sanzari
M
M
Sivieri
S
S
Piccinno
M G
MG
Argentiero
V
V
Rizzotti
P
P
Tavolato
B
B
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000276:immunology; D015703:Antigens, CD / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006684:HLA-DR Antigens / Q000276:immunology; D006801:Humans; D007376:Interleukin-2 / Q000276:immunology; D008137:Longitudinal Studies; D008297:Male; D008775:Methylprednisolone / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D006684:HLA-DR Antigens; D007376:Interleukin-2; D008775:Methylprednisolone